| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H11N3O5S |
| Molecular Weight | 321.309 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC=C(C=C1)\N=N\C2=CC(C(O)=O)=C(O)C=C2
InChI
InChIKey=NBSRUZQXRUNPNY-FOCLMDBBSA-N
InChI=1S/C13H11N3O5S/c14-22(20,21)10-4-1-8(2-5-10)15-16-9-3-6-12(17)11(7-9)13(18)19/h1-7,17H,(H,18,19)(H2,14,20,21)/b16-15+
| Molecular Formula | C13H11N3O5S |
| Molecular Weight | 321.309 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Salazosulfamide was studied for the treatment of ankylosing spondylitis. It was found that salazosulfamide efficacy is associated with N-acetyltransferase 1 polymorphisms and in particularly, NAT1 AA/GG genotype at 263 locus. However, future studies should be conducted to investigate these issues.
